VERAPAMIL HYDROCHLORIDE tablet, film coated, extended release United States - English - NLM (National Library of Medicine)

verapamil hydrochloride tablet, film coated, extended release

northwind pharmaceuticals, llc - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacolo

Sodium Chloride New Zealand - English - Medsafe (Medicines Safety Authority)

sodium chloride

baxter healthcare ltd - sodium chloride 0.9% - solution for infusion - 0.9 % - active: sodium chloride 0.9% - sodium chloride (0.9%) intravenous infusion is indicated for extracellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.

PHYSIONEAL 40 GLUCOSE 3.86 % WV Israel - English - Ministry of Health

physioneal 40 glucose 3.86 % wv

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; magnesium chloride hexahydrate 0.051 g/l; calcium chloride dihydrate 0.184 g/l; sodium bicarbonate 2.10 g/l; glucose monohydrate (as anhydrous) 38.6 g/l; lactic acid as sodium 1.68 g/l - calcium chloride - calcium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure; severe water retention; severe electrolyte imbalance; drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

Glucose 5% Intravenous Infusion BP Malta - English - Medicines Authority

glucose 5% intravenous infusion bp

baxter healthcare limited - glucose monohydrate - solution for infusion - glucose monohydrate 50 g/l - blood substitutes and perfusion solutions

Glucose 10% w/v Solution for Infusion Malta - English - Medicines Authority

glucose 10% w/v solution for infusion

baxter healthcare limited - glucose monohydrate - solution for infusion - glucose monohydrate 100 milligram(s)/millilitre - blood substitutes and perfusion solutions

Human Albumin 20% Biotest Low Salt Content Malta - English - Medicines Authority

human albumin 20% biotest low salt content

biotest pharma gmbh landsteinerstrasse 5, 63303 dreieich, germany - human plasma, protein - solution for infusion - human plasma protein 200 g/l - blood substitutes and perfusion solutions

Sodium Chloride 0.45% w/v and Glucose 5.0% w/v Solution for Infusion BP Malta - English - Medicines Authority

sodium chloride 0.45% w/v and glucose 5.0% w/v solution for infusion bp

baxter healthcare limited - glucose, sodium chloride - solution for infusion - glucose 5 percent weight/volume ; sodium chloride 0.45 percent weight/volume - blood substitutes and perfusion solutions

Sodium Valproate 100mg/mL Solution for Injection or Infusion New Zealand - English - Medsafe (Medicines Safety Authority)

sodium valproate 100mg/ml solution for injection or infusion

max health limited - sodium valproate 100 mg/ml - solution for injection - 100 mg/ml - active: sodium valproate 100 mg/ml excipient: dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate phosphoric acid sodium hydroxide water for injection - the treatment of patients with epilepsy or bipolar disorder, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

VALWOK sodium valproate 1000 mg/10 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

valwok sodium valproate 1000 mg/10 ml solution for injection ampoule

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - valwok is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

VALWOK sodium valproate 400 mg/4 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

valwok sodium valproate 400 mg/4 ml solution for injection ampoule

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - valwok is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.